Menderes Gulden, Black Jonathan, Schwab Carlton L, Santin Alessandro D
a Department of Obstetrics, Gynecology & Reproductive Sciences , Yale University School of Medicine , New Haven , CT , USA.
Expert Rev Anticancer Ther. 2016;16(1):83-98. doi: 10.1586/14737140.2016.1121108. Epub 2015 Dec 7.
The prognosis of patients with metastatic cervical cancer is poor with a median survival of 8-13 months. Despite the potency of chemotherapeutic drugs, this treatment is rarely curative and should be considered palliative only. In the last few years, a better understanding of Human papillomavirus tumor-host immune system interactions and the development of new therapeutics targeting immune check points have renewed interest in the use of immunotherapy in cervical cancer patients. Moreover, next generation sequencing has emerged as an attractive option for the identification of actionable driver mutations and other markers. In this review, we provide background information on the molecular biology of cervical cancer and summarize immunotherapy studies, targeted therapies, including those with angiogenesis inhibitors and tyrosine kinase inhibitors recently completed or currently on-going in cervical cancer patients.
转移性宫颈癌患者的预后较差，中位生存期为8至13个月。尽管化疗药物效力强大，但这种治疗很少能治愈，应仅视为姑息性治疗。在过去几年中，对人乳头瘤病毒与肿瘤宿主免疫系统相互作用的更好理解以及针对免疫检查点的新疗法的开发，重新激发了人们对在宫颈癌患者中使用免疫疗法的兴趣。此外，新一代测序已成为识别可操作的驱动突变和其他标志物的有吸引力的选择。在本综述中，我们提供了宫颈癌分子生物学的背景信息，并总结了免疫疗法研究、靶向治疗，包括最近在宫颈癌患者中完成或正在进行的抗血管生成抑制剂和酪氨酸激酶抑制剂治疗。
